wir dann nicht jetzt mind. bereits eine 1 vor den 83 € stehen haben? ;)
|
zu haben:
Williams said the drug had a significant effect on cognition among patients included in the study after 54 weeks of use during Phase I studies, and saw a decrease in amyloid deposits on the brain.
“The full data is going to be presented at an upcoming medical meeting. So, I’m just giving sort of the top-line view of what we’ve seen with the data,” Williams said, according to transcripts of the meeting. “But what I’ve said all along is that I thought we were running a good experiment.”
Williams said Biogen is planning to “very aggressively” start the Phase III program, generally the last step before seeking regulatory approval.
“[There are] lots of caveats, obviously, because we’re still early in the clinical program, but encouraging enough data to really have us pull the trigger on moving forward aggressively to plan for Phase III,” Williams added.
http://www.marketwatch.com/story/biogen-alzheimers-drug-skip…
research and development head Douglas Williams said that an interim analysis of a 194-patient phase one trial for BIIB-037, which it is jointly developing with Japan's Eisai drug firm, was good enough to push it straight into phase three. The numbers won't be formally reported until the spring, but Williams said that a statistically significant improvement in cognition appeared after 54 weeks of treatment.
http://news.investors.com/technology/120214-728675-biib-stoc…
Das Präparat ist speziell auf die Reduktion der Plaques ausgerichtet:
http://www.clinicaltrials.gov/ct2/show/NCT01677572
xxxxxxxxxxxx
Und Roche/Morphosys mit Gantenerumab sind mit einem ähnlichen Ansatz zeitlich weit voraus.
Stimmt, aber so dichter Nebel behindert dies wohl sehr stark?! Die finale "Interpunktion" ... verpasst? :p suggeriert mir Ironie, aber vielleicht täusche ich mich ja auch...
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
6 | 2.080 | Morphosys ! Wie Phönix aus der Asche? | Nebelland2005 | Highländer49 | 11.04.24 18:18 | |
202 | ueberlegungen zum kursverlauf der morphosys-aktie | spatzlmoden | verstehnix | 27.02.24 16:30 | ||
49 | 15.612 | MOR: Pipelinefortschritte führen zu Neubewertungen | ecki | holy | 06.02.24 09:39 | |
6 | 592 | Morphosys - Tradingziel 39 | newtrader2002de | Dr.Stock | 05.02.24 16:56 | |
14 | 1.202 | Morpho:Marktreife Partnerprojekte und Meilensteine | ecki | thüringer | 14.07.22 14:28 |